Sign In
Buy IMNM
$22.76
-0.320 (-1.39%)
At Close: Jul 31, 2026
Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120%
01:03pm, Sunday, 22'nd Feb 2026
Redmile Group added 695,000 shares of Immunome last quarter; the estimated trade size was $12.20 million based on average prices for the quarter. The quarter-end position value increased by $64.01 mil
Pre-Market Stock Futures: Futures are trading higher after a wild Wednesday that saw the market rally hard on the open on the non-farm payrolls print that blew away estimates, despite a significant de
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:00pm, Thursday, 05'th Feb 2026
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Thursday, 08'th Jan 2026
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced
Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference
08:00am, Tuesday, 06'th Jan 2026
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome
Insider Buying: Immunome (NASDAQ:IMNM) CEO Purchases $100,018.35 in Stock
04:52am, Friday, 02'nd Jan 2026
Immunome, Inc. (NASDAQ: IMNM - Get Free Report) CEO Clay Siegall purchased 4,729 shares of the firm's stock in a transaction on Tuesday, December 30th. The shares were purchased at an average cost of
Isaac Barchas Sells 383,200 Shares of Immunome (NASDAQ:IMNM) Stock
04:29am, Thursday, 25'th Dec 2025
Immunome, Inc. (NASDAQ: IMNM - Get Free Report) Director Isaac Barchas sold 383,200 shares of the stock in a transaction on Monday, December 22nd. The stock was sold at an average price of $21.74, for
Immunome (NASDAQ:IMNM) CEO Clay Siegall Buys 7,278 Shares of Stock
05:32am, Tuesday, 23'rd Dec 2025
Immunome, Inc. (NASDAQ: IMNM - Get Free Report) CEO Clay Siegall acquired 7,278 shares of the company's stock in a transaction dated Friday, December 19th. The shares were bought at an average cost of
Immunome: Maintaining "Strong Buy" On Successful RINGSIDE Trial With Varegacestat
02:44pm, Wednesday, 17'th Dec 2025
Immunome (IMNM) delivered statistically significant phase 3 RINGSIDE results for varegacestat in progressive desmoid tumors, achieving an 84% risk reduction in progression or death compared to placebo
Immunome Announces Pricing of Public Offering of Common Stock
08:16pm, Tuesday, 16'th Dec 2025
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announc
Immunome Target of Unusually Large Options Trading (NASDAQ:IMNM)
01:29am, Tuesday, 16'th Dec 2025
Immunome, Inc. (NASDAQ: IMNM - Get Free Report) was the recipient of unusually large options trading activity on Monday. Traders acquired 2,906 call options on the stock. This represents an increase o
Why Immunome Stock Surged Today
05:43pm, Monday, 15'th Dec 2025
A phase 3 study of varegacestat met its primary endpoint. The drug candidate could reduce the risk of disease progression or death in people with desmoid tumors by 84%.
Immunome Announces Proposed Public Offering of Common Stock
04:01pm, Monday, 15'th Dec 2025
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announc
Why Immunome, A Top 3% Stock, Just Rocketed On Its Rivalry With Merck KGaA
10:52am, Monday, 15'th Dec 2025
Top-notch biotech stock Immunome rocketed Monday after the company's treatment for desmoid tumors appeared to top an approved drug.
Immunome's experimental drug meets main goal in late-stage study
07:16am, Monday, 15'th Dec 2025
Immunome said on Monday its experimental drug met main goal in a late-stage study for patients with a rare type of tumor.
